Get started
Author

Irene Maria Briata

Observed names: Briata, Irene Maria, I. M. Briata, I.M. Briata, IM Briata, Irene M. Briata
ORCID: 0000-0003-0767-0026
Observed ORCID: 0000-0003-0767-0026
OpenAlex ID: A5062291346
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study
2023 · Matteo Lazzeroni, Matteo Puntoni, et al. · Journal of Clinical Oncology · 114
PDF
Taste and Smell Disorders in Cancer Treatment: Results from an Integrative Rapid Systematic Review
2023 · Tania Buttiron Webber, Irene Maria Briata, et al. · International Journal of Molecular Sciences · 61
PDF
Prebiotics, probiotics, synbiotics and postbiotics to adolescents in metabolic syndrome
2024 · Alessia Luzzi, Irene Maria Briata, et al. · Clinical Nutrition · 43
PDF
Predictors of Poor Seroconversion and Adverse Events to SARS-CoV-2 mRNA BNT162b2 Vaccine in Cancer Patients on Active Treatment
2021 · Tania Buttiron Webber, Nicoletta Provinciali, et al. · European Journal of Cancer · 43
PDF
The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
2018 · Marilena Petrera, Laura Paleari, et al. · BMC Cancer · 37
PDF
A Presurgical Study of Curcumin Combined with Anthocyanin Supplements in Patients with Colorectal Adenomatous Polyps
2021 · Irene Maria Briata, Laura Paleari, et al. · International Journal of Molecular Sciences · 28
PDF
Inflammatory and Metabolic Biomarker Assessment in a Randomized Presurgical Trial of Curcumin and Anthocyanin Supplements in Patients with Colorectal Adenomas
2023 · Debora Macis, Irene Maria Briata, et al. · Nutrients · 26
PDF
Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
2021 · Andrea DeCensi, Matteo Puntoni, et al. · Clinical Cancer Research · 24
Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
2023 · Carla Micaela Cuttica, Irene Maria Briata, et al. · Nutrients · 18
PDF
Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
2021 · Andrea DeCensi, Harriet Johansson, et al. · npj Breast Cancer · 13
PDF
Patient‐ versus physician‐reported outcomes in a low‐dose tamoxifen trial in noninvasive breast cancer
2021 · Tania Buttiron Webber, Domenico Marra, et al. · The Breast Journal · 10
PDF
Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast
2019 · Matteo Lazzeroni, Matteo Puntoni, et al. · The Breast · 7
Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
2025 · Harriet Johansson, Debora Macis, et al. · Clinical Cancer Research · 6
PDF
Low dose TamOxifen and LifestylE changes for bReast cANcer prevention (TOLERANT study): Study protocol of a randomized phase II biomarker trial in women at increased risk for breast cancer
2024 · Aliana Guerrieri-Gonzaga, Davide Serrano, et al. · PLoS ONE · 6
Exploring the Prognostic and Predictive Roles of Ki-67 in Endometrial Cancer
2023 · Laura Paleari, Mariangela Rutigliani, et al. · International Journal of Translational Medicine · 6
PDF
Home Se-Cure: A Home Care Service for Cancer Patients during the COVID-19 Pandemic
2021 · Tania Buttiron Webber, Silvia Giuliano, et al. · International Journal of Environmental Research and Public Health · 6
PDF
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation
2024 · Harriet Johansson, Aliana Guerrieri-Gonzaga, et al. · npj Breast Cancer · 5
PDF
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention
2025 · G. Aurilio, D. Serrano, et al. · npj Breast Cancer · 4
PDF
Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
2022 · Nicoletta Provinciali, Marco Greppi, et al. · Frontiers in Immunology · 3
PDF
Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase 3 trial in noninvasive breast cancer
2025 · Alessio Carbone, Martino Oliva, et al. · JNCI Journal of the National Cancer Institute · 2
Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study
2024 · Nicoletta Provinciali, Marco Piccininno, et al. · Reviews in Cardiovascular Medicine · 2
PDF
Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: a real-world study with implications for cancer prevention/interception
2025 · Martino Oliva, Monica Boitano, et al. · BMC Cancer · 1
350P Long-term gynaecological safety and benign breast disease on low-dose tamoxifen: 10-year results from the TAM-01 phase III trial
2025 · A. Carbone, M. Oliva, et al. · Annals of Oncology · 1
COVID-19 and malnutrition during the second wave: The experience in a low-Intensive Care Unit in Milan
2025 · L Vigna, MR Ingenito, et al. · Mediterranean Journal of Nutrition and Metabolism · 1
Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules
2024 · Davide Serrano, Harriet Johansson, et al. · JNCI Journal of the National Cancer Institute · 1
Works count: 67
Citation count: 471
H-index: 10
I10-index: 11
Year
Topic
Type